These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35699810)
1. Treatment of Oligometastatic Esophagogastric Cancer: A Spark of Light at the End of the Tunnel. Goense L Ann Surg Oncol; 2022 Aug; 29(8):4673-4675. PubMed ID: 35699810 [No Abstract] [Full Text] [Related]
2. Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE; van Rossum PSN; Nilsson M; Lordick F; Smyth EC; Rosati R; Nafteux P; D'Ugo D; Chaudry MA; Polkowkski W; Roviello F; Gockel I; Kolodziejczyk P; Haustermans K; Guckenberger M; Nordsmark M; Hawkins MA; Cervantes A; Fleitas T; van Cutsem E; Moehler M; Wagner AD; van Laarhoven HWM; van Hillegersberg R; Eur J Surg Oncol; 2023 Jan; 49(1):21-28. PubMed ID: 36184420 [TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer. Kroese TE; van Rossum PSN; van Hillegersberg R Ann Surg Oncol; 2022 Aug; 29(8):4858-4860. PubMed ID: 35307806 [No Abstract] [Full Text] [Related]
4. [Diagnosis and treatment of esophagogastric junction cancer]. Seto Y; Yamashita H Nihon Shokakibyo Gakkai Zasshi; 2015 Oct; 112(10):1769-75. PubMed ID: 26440679 [No Abstract] [Full Text] [Related]
5. [II. Treatment Strategy for Esophagogastric Junction Tumor]. Hashimoto T; Kurokawa Y; Miyazaki Y; Takahashi T; Tanaka K; Makino T; Yamazaki M; Nakajima K; Mori M; Doki Y Gan To Kagaku Ryoho; 2018 Sep; 45(9):1248-1253. PubMed ID: 30237365 [No Abstract] [Full Text] [Related]
6. The Management of Esophagogastric Cancers Enters a New Era. Shah MA Hematol Oncol Clin North Am; 2017 Jun; 31(3):xiii-xiv. PubMed ID: 28501094 [No Abstract] [Full Text] [Related]
8. The Current Status of Immunotherapies in Esophagogastric Cancer. Ku GY Surg Oncol Clin N Am; 2017 Apr; 26(2):277-292. PubMed ID: 28279469 [TBL] [Abstract][Full Text] [Related]
9. Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence? Hingorani M; Stubley H Oncol Res Treat; 2023; 46(7-8):312-319. PubMed ID: 37331340 [TBL] [Abstract][Full Text] [Related]
12. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868 [TBL] [Abstract][Full Text] [Related]
13. Esophagogastric junction and gastric adenocarcinoma: current challenges and future directions. Saba NF Oncology (Williston Park); 2014 Jun; 28(6):520-1. PubMed ID: 25134327 [No Abstract] [Full Text] [Related]
14. What's New in Gastric and Esophageal Cancers. Tanabe K Ann Surg Oncol; 2016 Nov; 23(12):3773. PubMed ID: 27638669 [No Abstract] [Full Text] [Related]
15. [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences]. Gockel I; Lordick F; Lyros O; Kreuser N; Hölscher AH; Wittekind C Chirurg; 2020 Jan; 91(1):41-50. PubMed ID: 31372677 [TBL] [Abstract][Full Text] [Related]
17. Three decades of oesophagogastric cancer care: now a curable disease. Phillips AW; Griffin SM Br J Surg; 2021 Jun; 108(6):595-597. PubMed ID: 33748863 [No Abstract] [Full Text] [Related]
18. Optimal management of esophageal adenocarcinoma: should we be CROSS? Smyth EC; Waddell TS; Cunningham D J Clin Oncol; 2014 Sep; 32(27):3080-1. PubMed ID: 25071100 [No Abstract] [Full Text] [Related]